FdaApplication
NDA 210251
Identifiers
- fda_app_no: NDA210251
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2018-02-07 |
Revenue by product
BIKTARVY
| Period | Revenue |
|---|---|
| Q2 2026 | $3.8B* |
| Q1 2026 | $3.4B* |
| Q4 2025 | $4.0B* |
| Q3 2025 | $3.7B* |
| Q2 2025 | $3.5B* |
| Q1 2025 | $3.1B* |
| Q4 2024 | $3.8B* |
| Q3 2024 | $3.5B* |
| Q2 2024 | $3.2B* |
| Q1 2024 | $2.9B* |
| Q4 2023 | $3.1B* |
| Q3 2023 | $3.1B* |
| Q2 2023 | $3.0B* |
| Q1 2023 | $2.7B* |
| Q4 2022 | $2.9B* |
| Q3 2022 | $2.8B* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BIKTARVY | BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | EQ 50MG BASE;200MG;EQ 25MG BASE | TABLET;ORAL |
| BIKTARVY | BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | EQ 30MG BASE;120MG;EQ 15MG BASE | TABLET;ORAL |
2 products